Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in hemodynamically stable patients with type 2 diabetes after worsening heart failure
NL-OMON50219Phase 3Active, not recruiting
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and type 2 diabetes mellitus (T2DM) comparing Sotagliflozin with Placebo (2 arms). Primary endpoints: Composite of cardiovascular death or hospitalization for heart failure in patients with LVEF <50% and Composite of cardiovascular death or hospitalization for heart failure in the total population. Started Nov 2018; status: active, not recruiting.
02
Drugs
sotagliflozin
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON50219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50219.